ADICET BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | -9.82% |
|
+1.38% | -22.22% |
Presenter SpeechUnknown Analyst (Analysts)[Audio Gap] Merrill Lynch. It is my pleasure to intr...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Calendar
2024-05-14
- Citizens JMP Life Sciences Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.47
USD
Average target price
9.6
USD
Spread / Average Target
+553.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.22% | 121M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Transcript : resTORbio, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03